Characteristic | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
---|---|---|---|---|
Gender | ||||
Female | 1.00 | 1.00 | ||
Male | 3.09(1.80–5.31) | < 0.001 | 2.58(1.42–4.69) | 0.002* |
Type of second-line drugs | ||||
lopinavir | 1.00 | 1.00 | ||
Atazanavir | 1.59(0.44–5.82) | 0.483 | 3.4(0.79–14.34) | 0.101 |
Other PIµ | 5.66(1.92–16.66) | 0.002 | 3.92(1.15–13.38) | 0.671 |
TB treatment | ||||
No | 1.00 | 1.00 | ||
Yes | 7.54(2.69–21.08) | < 0.001 | 5.65(1.76–18.09) | 0.004* |
Year of ART initiation | ||||
Before 2001 | 1.00 | 1.00 | ||
2001–2005 | 0.05(0.01–0.16) | < 0.001 | 0.06(0.02–0.22) | < 0.001* |
2006–2010 | 0.05(0.02–0.20) | < 0.001 | 0.07(0.02–0.28) | < 0.001* |
2011–2015 | 0.02(0.00–0.17) | < 0.001 | 0.03(0.00–0.26) | 0.002* |
Type of 1st line drug | ||||
NNRTI based | 1.00 | |||
NON-NNRTI∞ | 1.81(0.92–3.55) | 0.085 | – | – |
Other comorbidities | ||||
No | 1.00 | |||
Yes | 1.00(0.44–2.26) | 1.000 | – | – |
Age at start of 2nd line | ||||
0.99(0.97–1.01) | 0.300 | – | – | |
CD4 at start of second line | ||||
0.99(0.99–1.00) | 0.079 | – | – | |
Duration on 1st line | ||||
1.07(0.96–1.18) | 0.210 |